Investment case
Positioned for profitable growth, and supported by our purpose, strategy, culture and business model, we aim to deliver exceptional and long-term value for our shareholders.
Highly attractive market
Vimian operates within the global animal health market, historically characterised by strong, resilient, and non-cyclical growth. Market development is supported by a number of attractive underlying and secular growth drivers; increase in pet ownership, the humanisation of pets, the increased awareness of available products and treatments for companion animals, as well an aging pet population.
Vimian targets global niches of this market with particular unmet medical needs and sustainable above-market growth potential. The company believes that its addressable market will increase to EUR 45 billion by 2030, corresponding to around 7 per cent CAGR 2023-2030.
Strong financial track record
Vimian has a history of high and profitable growth. From 2018 to 2025, the Company demonstrated 49 per cent revenue CAGR reaching proforma revenue of EUR 430.4 million for the twelve months ending 31 December 2025. Over the same period, the company achieved adjusted EBITA CAGR of 61 per cent reaching pro-forma adjusted EBITA of EUR 108.9 million. Organic growth reached 6 per cent in 2025.
Fragmented market with untapped potential
Vimian partners with exceptional entrepreneurs and management teams to support accelerated innovation and growth. Between 2015 - 2025, with a selective approach to M&A, Vimian has successfully completed 61 acquisitions in more than 15 countries across Europe, North America and APAC.
Vimian brings businesses with a strong industrial logic together to complement its product portfolios, access new geographies, customer bases and new technologies. The market remains highly fragmented, and Vimian believes there are significant opportunities for further value-creative M&A.
Cash generative business
The asset-light nature of Vimian’s business, with Capex (excl. acquisitions) of c. 4 per cent of revenue and net working capital of c. 23 per cent of proforma revenue, supports strong cash flow generation.
The new financial target, adopted in March 2024, of annual adjusted EBITA above EUR 300m by 2030, reflects Vimian’s ambition to build shareholder value through strong profit growth with a high level of cash generation.